18
Participants
Start Date
August 31, 2009
Primary Completion Date
July 31, 2010
Study Completion Date
July 31, 2010
nonacog beta pegol
Cohort to receive a single dose of 25U/kg nonacog beta pegol administered intravenously (into the vein)
nonacog beta pegol
Cohort to receive a single dose of 50U/kg nonacog beta pegol administered intravenously (into the vein)
nonacog beta pegol
Cohort to receive a single dose of 100U/kg nonacog beta pegol administered intravenously (into the vein)
Novo Nordisk Investigational Site, Copenhagen
Novo Nordisk Investigational Site, Berlin
Novo Nordisk Investigational Site, Richmond
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Hanover
Novo Nordisk Investigational Site, Cincinnati
Novo Nordisk Investigational Site, Bonn
Novo Nordisk Investigational Site, Frankfurt/M.
Novo Nordisk Investigational Site, Lyon
Novo Nordisk Investigational Site, Le Kremlin-Bicêtre
Novo Nordisk Investigational Site, Portland
Novo Nordisk Investigational Site, Kashihara-shi, Nara
Novo Nordisk Investigational Site, Nagoya-shi, Aichi
Novo Nordisk Investigational Site, Nishinomiya-shi
Novo Nordisk Investigational Site, Stockholm
Novo Nordisk Investigational Site, London
Novo Nordisk Investigational Site, London
Novo Nordisk Investigational Site, Manchester
Novo Nordisk Investigational Site, Oxford
Lead Sponsor
Novo Nordisk A/S
INDUSTRY